Enanta Pharmaceuticals Inc
NASDAQ:ENTA

Watchlist Manager
Enanta Pharmaceuticals Inc Logo
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Watchlist
Price: 12.67 USD 1.44% Market Closed
Market Cap: 365.7m USD

Operating Margin

-130.7%
Current
Improving
by 34.5%
vs 3-y average of -165.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-130.7%
=
Operating Income
$-85.3m
/
Revenue
$65.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-130.7%
=
Operating Income
$-85.3m
/
Revenue
$65.3m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
359.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
380.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
181.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
157.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 14 112 companies
14th percentile
-130.7%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Enanta Pharmaceuticals Inc
Glance View

Market Cap
365.7m USD
Industry
Biotechnology

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.

ENTA Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-130.7%
=
Operating Income
$-85.3m
/
Revenue
$65.3m
What is Enanta Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Enanta Pharmaceuticals Inc is -130.7%, which is above its 3-year median of -165.1%.

How has Operating Margin changed over time?

Over the last 3 years, Enanta Pharmaceuticals Inc’s Operating Margin has increased from -143.6% to -130.7%. During this period, it reached a low of -193% on Dec 31, 2023 and a high of -130.7% on Oct 30, 2025.

Back to Top